Jacobs Levy Equity Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18.5M | Buy |
162,810
+5,629
| +4% | +$640K | 0.07% | 221 |
|
|
2025
Q1 | $16.5M | Buy |
+157,181
| New | +$16.5M | 0.07% | 254 |
|
|
2024
Q2 | – | Sell |
-14,762
| Closed | -$1.08M | – | 1010 |
|
|
2024
Q1 | $1.08M | Sell |
14,762
-5,517
| -27% | -$403K | ﹤0.01% | 702 |
|
|
2023
Q4 | $1.45M | Sell |
20,279
-4,053
| -17% | -$289K | 0.01% | 659 |
|
|
2023
Q3 | $1.46M | Buy |
+24,332
| New | +$1.46M | 0.01% | 614 |
|
|
2023
Q2 | – | Sell |
-3,845
| Closed | -$283K | – | 1034 |
|
|
2023
Q1 | $283K | Buy |
+3,845
| New | +$283K | ﹤0.01% | 872 |
|